 SAN DIEGO, May 6, 2021 PRNewswire -- MEI Pharma, Inc. NASDAQ: MEIP, a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended March 31, 2021 and highlighted recent corporate progress. The first several months of 2021 have been very eventful for MEI, highlighted by the completion of enrollment in the follicular lymphoma efficacy population arm of the zandelisib TIDAL study. 